# Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma

> **NCT01878188** · PHASE1 · COMPLETED · sponsor: **Anchiano Therapeutics Israel Ltd.** · enrollment: 38 (actual)

## Conditions studied

- Transitional Cell Carcinoma of Bladder

## Interventions

- **DRUG:** BC-819/PEI
- **DRUG:** BCG Vaccine

## Key facts

- **NCT ID:** NCT01878188
- **Lead sponsor:** Anchiano Therapeutics Israel Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2015-10
- **Final completion:** 2017-10
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2019-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01878188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01878188, "Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01878188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*